# US 8,278,285 B2 · Gastric carcinoma gene ZNF312b, a protein translated from the gene, and a diagnostic kit and a screening method for anticancer agents using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,285 B2
- Document ID: US8278285B2
- Status: Granted
- Kind: B2
- Application number: 12/594,843
- Filed: 2008-08-06
- Published: 2010-06-24
- Granted: 2012-10-02
- Earliest claimed: 2007-08-06
- Assignees: Korea Research Institute of Bioscience and Biotechnology
- Inventors: Nam-Soon Kim; In-Sung Song; Nang-Su Oh; So-Young Jeong; Ga-Hee Ha; Yeo-Jin Jeon; Jeong-Min Kim; Cheol-Hee Kim; Hyun-Taek Kim
- Web page: https://patentgrep.com/patent/US8278285B2

## CPC

- C07K 14/47: from mammals
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a diagnostic marker containing ZNF312b gene and the fragment thereof, a diagnostic method for stomach cancer and a screening method for stomach cancer inducers or inhibitors using the same. ZNF312b gene expression is specifically increased in stomach cancer. And the over-expression or the under-expression of the gene affects activation or inhibition of cell proliferation and tumor formation of a stomach cancer cell line and cell proliferation signal transduction system as well to induce stomach cancer at last. Therefore, ZNF312b marker gene can be effectively used for diagnosis of stomach cancer, construction of a stomach cancer animal model, prevention and treatment of stomach cancer and development of a stomach cancer specific anticancer agent.

## Claims

### Claim 1

A method for inhibiting proliferation of gastric tumor cells comprising administering to said tumor cells an effective amount of a ZNF312b (Zinc finger protein 312b) gene expression inhibitor, wherein the ZNF312b gene expression inhibitor is:
an antisense polynucleotide with a complementary sequence to the mRNA transcribed from a ZNF312b gene comprising the nucleotide sequence as set forth in SEQ ID NO:1 or a fragment thereof containing the carboxy-terminal region of ZNF312b gene comprising the nucleotide sequence coding the amino acid sequence as set forth in SEQ ID NO:20, thereby specifically inhibiting expression of the ZNF312b gene,
a siRNA (small interfering RNA) molecule which comprises a sequence having the complementary sequence to the mRNA transcribed from the ZNF312b gene comprising the nucleotide sequence as set forth in SEQ ID NO:1 or a fragment thereof containing the carboxy-terminal region of the ZNF312b gene comprising the nucleotide sequence coding the amino acid sequence as set forth in SEQ ID NO:20, thereby specifically inhibiting expression of the ZNF312b gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the siRNA molecule is selected from the group consisting of the siRNA as set forth in SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO: 8.
